glp-1 conversion Market Overview: Agonists and the Obesity Market | Blog 6/n: The GLP-1 Goldrush has

Tirzepatide, a new era of dual-targeted treatment for diabetes and obesity: A mini-review

The same week those letters went out, A major telehealth platform announced a partnership with a brand-name GLP-1 manufacturer in early 2026, agreeing to shift toward branded medications and pull back most compounded GLP-1 advertising

Here is link to study: a1c reduction, weight benefits, lower side effectsonce it goes PO (for needle averse) & cost lowered (maybe?) - I see it utilized even more wondering how plans are building this inside their MLR strategy The metformin-to-GLP-1 shift in first-line prescribing is one of the fastest I have seen across any therapy class

Combining GLP-1 receptor agonists with DPP-4 inhibitors is generally not recommended due to limited additive benefit

However, the interpretation of these outcomes is complex, as they involve the confounding effects of drug combination, extended follow-up, and changes in conception-related behaviors